Fragile X premutations are known to be a risk factor for diminished ovarian function at a relatively young age. We studied endocrine profiles of female fragile X family members (n ⍧ 79) at risk of premature ovarian failure (POF). Of these 79 women aged <40 years, 45 had menstrual cycles, and 34 were using oral contraceptives. Of the women with menstrual cycles, the premutation carriers had higher serum FSH concentrations than women who were not carrying the premutation. Even premutation carriers with regular cycles showed increased serum FSH concentrations. Moreover, premutation carriers using oral contraceptives also demonstrated increased serum FSH concentrations. Irrespective of whether oral contraceptives were used, a serum FSH concentration of ≥15 IU/l was more common in the premutation carriers than in the other women. One premutation carrier using oral contraceptives had a serum FSH concentration of >40 IU/l, the threshold that defines POF. We confirmed that premutation carriers with menstrual cycles demonstrate premature ovarian dysfunction. However, we also found endocrine signs of unrecognized ovarian dysfunction in premutation carriers using oral contraceptives, despite endocrine alterations by oral contraceptives. Premutation carriers may have a poorer prognosis for future pregnancy, either achieved spontaneously or by assisted reproductive technology. We recommend that premutation carriers should be counselled not to wait too long if they wish to start a family.
Introduction
Hawkins Uzielli et al., 1999; Hundscheid et al., 2000; Marozzi et al., 2000) . POF is defined as a condition of The fragile X syndrome is an X-linked disorder, which is spontaneous menopause, or secondary hypergonadotrophic caused by the absence of the fragile X mental retardation hypo-oestrogenic amenorrhoea that occurs before the age of protein (FMRP). Most commonly, this lack of FMRP results 40 years. from the trinucleotide repeat expansion that occurs in the With expanding knowledge and progression in diagnostics FMR1 gene promoter (Verkerk et al., 1991) . This expansion and therapeutics, counselling should be given, not only about eventually results in a process of hyper-methylation, which the genetic risks, but also about preimplantation genetic makes the gene transcriptionally inactive (Imbert et al., 1998) . diagnosis (PGD) and, therefore, IVF. For this reason premutaNormally, there are Ͻ50 of such (CGG) repeats. Alleles with tion carriers should be counselled about the risk of fertility repeat sizes of 50-200 are classified as premutations, whereas problems related to POF. the full mutation contains at least 200 repeats. Female carriers Presently, little is known about the endocrinology of preof the full mutation may show signs of the fragile X syndrome.
menopausal premutation carriers and the spontaneous pregFor many years it was thought that female premutation carriers nancy rates or pregnancy rates after IVF procedures. To did not show any phenotypical abnormalities, except for the determine whether young fragile X premutation carriers show risk of repeat expansion when the mutation was transmitted endocrine signs of premature ovarian dysfunction, we investito their children. This was supported by the fact that FMRP is gated the endocrine profiles of young women from fragile X produced at normal concentrations by alleles in the premutation families who were using combined oral contraceptives, and range (Feng et al., 1995) . However, there is now growing those who did not. To our knowledge, only one pilot study evidence that the fragile X premutation is a significant risk factor for premature ovarian failure (POF) (Allingham- (Braat et al., 1999) and one larger study (Murray et al., 1999) have been conducted on the endocrinology of premenopausal technology setting (Creus et al., 2000) . In such studies, women with an FSH concentration of ജ15 IU/l have lower spontaneous premutation carriers not using combined oral contraceptives. pregnancy rates as well as lower pregnancy rates after IVF The latter study determined endocrine profiles in blood samples procedures than women with a serum FSH concentration of taken on one occasion between days 1 and 10 of the menstrual Ͻ15 IU/l (Scott and Hofmann, 1995) . We evaluated whether cycle from premenopausal premutation carriers and women not more premutation carriers aged Ͻ40 years demonstrated a carrying a premutation aged 17-53 years. The premenopausal serum FSH concentration of ജ15 IU/l than women not carrying fragile X premutation carriers showed higher serum concentraa premutation. tions of FSH than the other women (i.e. full mutations and As FSH concentrations increase with age in women with controls). The present study, however, focused on women aged regular menstrual cycles (Lee et al., 1988) , we evaluated Ͻ40 years, because these women are at risk of developing whether premutation carriers with normal cycles had higher POF, which occurs, by definition, prior to the age of 40 years.
FSH concentration than women not carrying the premutation Hence, we studied the endocrine profiles in women with with normal cycles, after correcting for age. menstrual cycles and in those who were using oral contraceptives.
Women who are using combined oral contraceptives will Materials and methods not show any overt signs of diminished ovarian function.
Patients
Owing to the administration of oestrogens and the monthly
In a large ongoing study on previously diagnosed fragile X families withdrawal bleeding, most women who are using combined (current number of participating families is 71) we approached women oral contraceptives will not know whether they are peri-or who met the following criteria: (i) aged 18-40 years; (ii) previously post-menopausal. Combined oral contraceptives suppress the screened for fragile X mutations; and (iii) with a normal cytogenetic hypothalamic-pituitary-ovarian axis (Mishell et al., 1977) .
karyotype.
Suppression of FSH release seems to be an exclusive effect
We selected women from our ongoing study who either menstruated at least once every 3 months or were using combined oral contraceptof 17α-ethinyl oestradiol and inhibin B, whereas the release ives. All participants gave informed consent for the study, which was of LH is modified by both 17α-ethinyl oestradiol and the approved by the institutional review board. As in a previous paper progestin components. Combined oral contraceptives inhibit (Murray et al., 1999) , the participants were further stratified into normal ovarian function, result in anovulation and cause premutation carriers and the other women. The latter group comprises withdrawal bleeding. During the pill-free interval, the function women who were not carrying a premutation, i.e. the women with of the hypothalamic-pituitary-ovarian axis is restored. Serum either a normal or a fully-mutated FMR1 gene (as from here designated concentrations of FSH, LH and 17β-oestradiol start to rise, as: the other women). As serum FSH concentrations are higher in with a parallel increase in inhibin B (Renier et al., 1998) .
women who smoke cigarettes (El-Nemr et al., 1998) we stratified the Gonadotrophin concentrations return to the normal early follicwomen into two subcategories, i.e. women who were currently ular phase concentrations (Cohen and Katz, 1979, 1981) , smoking and those who were not (ex-and non-smokers).
although the 17β-oestradiol concentrations are still lower than Study protocol those in the early follicular phase (Van der Spuy et al., 1990) .
In this study, normal menstrual cycles were defined as regular cycles
We analysed the serum concentrations of FSH and 17β-with no more than 5 days intercycle time variation and a length of oestradiol in women aged Ͻ40 years. The serum inhibin B profiles of the premutation carriers with those of the other women, while adjusting for the effects of age and smoking. To stabilize the variance, we first transformed our data by taking the natural logarithm (ln) of the serum concentrations. Sometimes more than one carrier from the same family was participating in this study. To avoid familial influences on FSH concentrations, we reanalysed the data while including only one randomly selected premutation carrier per family. In case of more than one woman not carrying the premutation (the other women), the analysis was conducted in an identical manner, thus only including one randomly selected other woman. A χ 2 test was used to compare the significance of differences in the number of premutation carriers with a serum FSH of ജ15 IU/l to the number of the other women with a serum FSH concentration of ജ15 IU/l. All analyses were performed with the Statistical Package for Social Sciences software (SPSS), version 9.0. P Ͻ 0.05 was considered to be statistically significant.
Results
Our study group comprised 79 women and was divided into two groups of women: those who had menstrual cycles, and those who were using oral contraceptives. For the sake of clarity, each group will be discussed separately.
women with menstrual cycles.
Women with menstrual cycles (n ⍧ 45)
A total of 17 women were carriers of the fragile X premutation, of the other women was 6.65 Ϯ 2.74 IU/l (Table I) . Linear regression analysis demonstrated that after adjustment for age while 28 were not (other women). The latter group comprised 16 women with a normal FMR1 gene and 12 who had a full and smoking behaviour, the premutation carriers still had significantly higher serum FSH concentrations than the other mutation. One premutation carrier had a serum progesterone concentration of 16 nmol/l on day 3 of the menstrual cycle.
women (P ϭ 0.002). A serum FSH of ജ15 IU/l was observed in four out of 16 premutation carriers aged Ͻ40 years ( Figure  This concentration probably reflected the luteal phase concentration of the previous cycle, so this woman was excluded 1), but not in any of the 28 other women (two-tailed χ 2 test; P ϭ 0.013). from further analysis. The mean age of the premutation carriers and the other women was 36 Ϯ 2.2 and 34 Ϯ4.7 years Since our analyses sometimes included more than one premutation carrier or other women from the same family, we respectively (Table I) . Six (37.5%) premutation carriers and six (21.4%) of the other women were currently smoking. The reanalysed our data as described in above. It was demonstrated that after correction for possible familial influences on FSH, serum FSH in the premutation carrier group was in the range 5.4-39.1 IU/l, while that in the other women was the premutation carriers had significantly higher FSH concentrations than the other women (P ϭ 0.002). 1.8-12.9 IU/l (Figure 1) .
Analysing the data from all women irrespective of their In addition, we assessed serum inhibin B concentrations. In the premutation carrier group, they were in the range 2.0-148 menstrual cycle pattern, the mean serum FSH concentration of the premutation carriers was 15.0 Ϯ 11.7 IU/l, while that ng/l, while in the other women they were 2.0-169 ng/l. The the premutation carriers and 8.35 Ϯ 3.5 IU/l in the other women (Table I) . After adjusting for age and smoking behaviour, linear regression analysis demonstrated that the premutation carriers still had significantly higher serum FSH concentrations (P ϭ 0.001). We observed a serum FSH of ജ15 IU/l in significantly more of the premutation carriers than in the other women (χ 2 test; P ϭ 0.013). Overall, this was the case in seven (54%) out of the 13 premutation carriers, and in two (9.5%) out of the 21 other women (Figure 2 ). We observed one 34 year old premutation carrier who had an FSH concentration of 54 IU/l. After correcting for possible familial influences in FSH, it was shown that the carriers had significantly higher FSH concentrations than the other women (P ϭ 0.001). Serum inhibin B ranged from 2.0 to 207 ng/l in the premutation carrier group and from 2.0 to 202 ng/l in the other women. Linear regression analyses did not demonstrate any significant difference in serum inhibin B and in 17β-oestradiol between the premutation carriers and the other women. Since fragile X premutations are known to be a risk factor for diminished ovarian function at a relatively young age, the aim mean serum inhibin B concentration was 52.8 Ϯ 42.6 ng/l in the of this study was to investigate the endocrine profiles of premutation carriers, and 70.7 Ϯ 37.8 ng/l in the other women premenopausal women out of fragile X families. To date, only (Table I) , which was not significantly different. The concentratwo studies have been conducted on the endocrinology of tions of 17β-oestradiol were evenly distributed over the two premenopausal carriers of the fragile X premutation. These groups.
studies found an increased serum FSH concentration in preTo evaluate whether the premutation carriers with normal mutation carriers (Braat et al., 1999; Murray et al., 1999) . The cycles had endocrine signs of diminished ovarian function, we present study confirms the finding that the premutation carriers first excluded the data from the women with abnormal menhad higher serum concentrations of FSH than the other women, strual cycles (n ϭ 7). We subsequently analysed the data from irrespective of menstrual cycle pattern. Even in women with the women with normal cycles (n ϭ 37). The mean serum normal menstrual cycles, the premutation carriers had higher FSH concentration was 11.0 Ϯ 7.89 IU/l in the regularly serum FSH concentrations than the other women. This may menstruating premutation carriers, and 6.92 Ϯ 2.71 IU/l in the indicate that, even if the premutation carriers have normal other women (see Table I ). Multiple linear regression analyses cycles, they may already be suffering from ovarian ageing, demonstrated that these premutation carriers had significantly which would be in line with the high occurrence of POF higher serum FSH concentrations than the other women with in premutation carriers (Allingham-Hawkins et al., 1999) . a normal cycle (P ϭ 0.029). A serum FSH of ജ15 IU/l was Furthermore we found that, of the women who were using observed in one out of 12 premutation carriers, but in none of combined oral contraceptives, the premutation carriers also the 25 other women (P Ͼ 0.05). There were no significant had significantly higher serum FSH concentrations than the differences in serum inhibin B and 17β-oestradiol.
other women.
Women on oral contraceptives (n ⍧ 34)
A serum FSH concentration of ജ15 IU/l was more frequently observed in premutation carriers (both oral contraceptive users, All these women were using low-dose (Ͻ50 µg 17α-ethinyl and non-users) aged Ͻ40 years than in other women, which oestradiol) combined oral contraceptives. A total of 13 women suggests that these premutation carriers have a poorer prognosis were premutation carriers, while the 21 other women were for future pregnancy. However, most data concerning the not. In the latter group, 11 women had a normal FMR1 gene predictive value of FSH are from studies in an assisted and 10 had a full mutation.
reproductive technology setting. It remains questionable The mean age of the premutation carriers and other women whether these findings also apply to women who are not being was 34 Ϯ 5.3 years and 31 Ϯ 4.5 years respectively (Table  treated for infertility problems. I). Six (46%) premutation carriers and five (24%) of the other An item of concern was that sometimes more than one women were currently smoking.
female per family participated in our study. We investigated Endocrine profiles were assessed in the blood samples whether familial bias factors influencing FSH concentrations obtained on the last day of the 7-day pill-free interval. Serum were present in our data. It was found that after correction for FSH ranged from 6.0 to 54 IU/l in the premutation carrier multiple familial participation premutation carriers had higher group and from 3.5 to 16 IU/l in the other women (Figure 2) . The mean serum FSH concentration was 20.4 Ϯ 13.5 IU/l in FSH concentrations than the other women. This was the case in both carriers who were using oral contraceptives and in ing women, we had to exclude seven women from this analysis because they reported having abnormal menstrual cycles (four those who were not.
Although inhibin B was assumed to be the first marker of premutation carriers and two other women). In the women with abnormal cycles, the premutation carriers only differed ovarian ageing (Welt et al., 1999) , clinical relevance is still elusive. Furthermore, to our knowledge, there are no reports from the other women in having significantly higher serum FSH concentrations (t-test; P ϭ 0.043). In the premutation on the interpretation of serum inhibin B concentrations in the pill-free interval. Nevertheless, we measured inhibin B and carriers the mean serum FSH was 27 IU/l, while the mean serum inhibin B was 11.1 ng/l. In the other women, these found no statistically lower concentrations in premutation carriers than in the other women; neither in the contraceptive concentrations were 4.40 IU/l and 79.7 ng/l respectively (Table  I) . In our view, it seems that especially the premutation carriers users, nor in the women with menstrual cycle. This is in line with a recent study (among a comparable study population) with abnormal cycles demonstrated signs of ovarian ageing, which may have caused these cycle abnormalities. However, that did not find a significant association either, although the authors consider their inhibin data to be inconclusive (Murray the numbers were small; further research may help to elucidate this issue. et al., 2000) . Therefore, it remains questionable whether the assessment of inhibin B has any clinical relevance.
Figures 1 and 2 depict a few outlying observations, which may represent a subset of women who had ovarian dysfunction. Young premutation carriers who are using combined oral contraceptives will not be able to recognize peri-menopausal All these outlying observations are accounted for by premutation carriers. However, not all premutation carriers had endosigns, due to the administration of exogenous oestrogens. In the present study, we demonstrated that unrecognized ovarian crine signs of ovarian reserve diminution, and therefore it is possible that the group of premutation carriers could have been dysfunction, or even worse, POF (as was the case in the premutation carrier with a serum FSH of 54 IU/l) was present divided in at least two subgroups with different phenotypes and, possibly, genotypes. Recently, we found that women with a in female carriers of the fragile X premutation using combined oral contraceptives. To our knowledge, this is the first report paternally-inherited premutation (PIP) have a high risk for developing POF, whereas women with a maternally-inherited on unrecognized diminished ovarian function in women who are using combined oral contraceptives. premutation (MIP) do not (Hundscheid et al., 2000) . We evaluated whether a parent-of-origin effect could be detected In women who have just started using oral contraceptives, the suppressed FSH concentrations return to the normal baseline in the endocrine profiles. Therefore, we analysed the data on all the premutation carriers in whom the parental origin of the concentration (of the control cycle) during the pill-free period (Cohen and Katz, 1979; Cohen and Katz, 1981) . In peri-or premutation could be determined. We found no associations between ovarian dysfunction and the parental origin of the post-menopausal women who have just started using oral contraceptives, FSH is not restored to the previously established premutation. The numbers, however, were too small to draw any firm conclusion. Further research is warranted to determine control baseline concentration during the short pill-free interval (Creinin, 1996) . All these reports compared the baseline whether women with a PIP have a different endocrine profile from other women. concentration of FSH with the hormone concentration at the end of the pill-free interval. Thus, it seems reasonable to
In conclusion, premutation carriers demonstrated increased serum FSH concentrations in comparison with the other conclude that endocrine profiles assessed on the last day of the pill-free interval do not necessarily reflect the (nonwomen. This applies to premutation carriers with regular cycles as well as to those who were using oral contraceptives. suppressed) baseline concentrations. As the present study lacked data on baseline FSH, it was not possible to determine Moreover, serum FSH concentrations of ജ15 IU/l were more frequently observed in premutation carriers, irrespective of whether the serum FSH values returned to baseline. It is possible that women with high serum FSH concentrations may the use of oral contraceptives. Both findings suggest that premutation carriers show endocrine signs of diminished have even higher baseline concentrations of FSH. In the present study, the premutation carriers had higher serum FSH ovarian function, which is in line with the observation that premutation carriers have a high risk of developing POF. concentrations and so we expect that especially the premutation carriers will have even higher baseline FSH concentrations.
Women with an FSH of ജ15 IU/l have lower spontaneous pregnancy rates as well as lower pregnancy rates after IVF Four women were using combined oral contraceptives to regulate their irregular cycles: one premutation carrier (36 than women with a serum FSH of Ͻ15 IU/l (Scott and Hofmann, 1995) . Hence, premutation carriers need to be years, FSH 34.9 IU/l) and three other women (aged 25, 28 informed about this risk, especially if they are considering and 28 years, with serum FSH concentrations of 9.2, 6.7 and PGD, which implies IVF. In the case of mild FSH elevations, 7.1 IU/l respectively). It is possible that, at that time, these it might be possible to achieve pregnancy with assisted irregular cycles were caused by diminished ovarian function.
reproductive technology. At present, we can only advise young In order to minimize the risk of potential selection bias (by carriers of the fragile X premutation not to postpone starting including women who were taking combined oral contracepta family for too long. ives for diminished ovarian function), we also performed a multiple regression analysis which excluded these four women from the analysis. The FSH concentrations remained signific
